SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: muddphudd who wrote (468)11/18/1998 2:44:00 PM
From: John S. Baker  Read Replies (1) of 586
 
I spoke with Amanda Rice at CYPB this morning, asking for her best take on the FDA's actions and the possible timeline for approval of the Prosorba for RA.

Her response was basically that the panel had turned its information over to the FDA and that things were now entirely in the hands of the FDA.

As to timing, she suggested that my guess was as good as hers regarding the FDA's timeline, but noted that Immunex (Enbrel) had heard within 2-3 months following their panel's findings.

So her *guess* is that, if the same timetable exists for the Prosorba column, they would hope to hear "by the end of the year" but nobody knows for sure.

Hope that helps.

JSb.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News